511 related articles for article (PubMed ID: 27470620)
1. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
Luo XD; Chen XP; Chen R; Chen XF; Huang J
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
3. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
Luo XD; Chen XP; Chen XF
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):896-901. PubMed ID: 29325289
[No Abstract] [Full Text] [Related]
4. [Clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a therapy].
Luo XD; Chen XP; Chen XF
Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):583-588. PubMed ID: 29056007
[No Abstract] [Full Text] [Related]
5. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
6. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
7. [HBeAg seroconversion achieved by sequential peginterferon alfa-2a therapy in chronic hepatitis B patients with unsatisfactory end point following entecavir treatment].
Chen XF; Chen XP; Ma XJ; Chen WL; Luo XD; Liao JY
Zhonghua Gan Zang Bing Za Zhi; 2013 Jul; 21(7):502-5. PubMed ID: 24074707
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the factors for predicting the outcomes of interferon-α and entecavir treatments for chronic hepatitis B with positive HBeAg].
Xie Z; Zhou F; Zhou Y
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):878-81. PubMed ID: 23803202
[TBL] [Abstract][Full Text] [Related]
11. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
[TBL] [Abstract][Full Text] [Related]
12. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
[TBL] [Abstract][Full Text] [Related]
13. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
14. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
15. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
[TBL] [Abstract][Full Text] [Related]
16. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
17. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF
J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
[TBL] [Abstract][Full Text] [Related]
18. [Clinical effect and safety of pegylated interferon-α-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients].
Hou FQ; Yin YL; Zeng LY; Shang J; Gong GZ; Pan C; Zhang MX; Yin CB; Xie Q; Peng YZ; Chen SJ; Mao Q; Chen YP; Mao QG; Zhang DZ; Han T; Wang MR; Zhao W; Liu JJ; Han Y; Zhao LF; Luo GH; Zhang JM; Peng J; Tan DM; Li ZW; Tang H; Wang H; Zhang YX; Li J; Zhang LL; Chen L; Jia JD; Chen CW; Zhen Z; Li BS; Niu JQ; Meng QH; Yuan H; Sun YT; Li SC; Sheng JF; Cheng J; Sun L; Wang GQ
Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):589-596. PubMed ID: 29056008
[No Abstract] [Full Text] [Related]
19. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
20. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
Luo X; Yu JX; Xie L; Ma WJ; Wang LH
Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
